Major platform update adds psychiatric data, neurology commercial intelligence and a new Blood-Brain Barrier search feature.
Beacon Intelligence has announced a significant expansion of its neuroscience offering, strengthening the Beacon Neuroscience platform with two major data additions and a new search feature designed to help users assess opportunities faster and navigate complex datasets more efficiently.
The latest enhancements include the addition of psychiatric drugs and trials data, neurology deals and companies’ intelligence, and the launch of a new Blood-Brain Barrier (BBB) search column. Together, the updates mark an important step forward for Beacon Neuroscience as a specialist platform supporting organisations operating across neurological and psychiatric drug development.
Originally launched to bring greater clarity to one of the most scientifically challenging areas of life sciences, Beacon Neuroscience was developed with input from the scientific community to help users find, analyse and act on the information that matters most. These latest developments build on that foundation by broadening both the scientific and commercial intelligence available to subscribers.
Expanded psychiatric drug and trial coverage
Beacon Neuroscience now offers significantly deeper coverage of psychiatric disorders, giving users access to a growing dataset spanning both preclinical and clinical development activity.
The expansion includes more than 1,500 psychiatric drugs and over 4,500 psychiatric clinical trials, across psychiatric disorders including schizophrenia, depression, stress, and addiction, amongst others, broadening Beacon Neuroscience’s coverage of psychiatric drug development and giving users deeper insight into pipeline activity across this important area of CNS research.
For pharmaceutical, biotech and investment teams, the additional data supports faster opportunity assessment and a more informed understanding of a highly competitive market.
New neurology deals and companies intelligence
Alongside the psychiatric data expansion, Beacon Intelligence has also launched dedicated neurology deals and companies’ data within the platform.
Beacon Neuroscience subscribers can now access intelligence covering more than 9,000 deals and 5,600 companies, helping users analyse mergers and acquisitions, licensing agreements, partnerships, collaborations, financings and wider market activity across the neurology sector.
The new commercial dataset has been designed to work alongside Beacon’s scientific and clinical intelligence, giving users a more complete view of the market from early-stage innovation through to strategic transactions. This enables users to identify potential partners, benchmark comparable deals, monitor competitor activity and understand where investment momentum is building across neurological indications.
By bringing scientific, clinical and commercial intelligence together in one place, Beacon Neuroscience offers users a more joined-up view of the market and reduces the time spent gathering intelligence from multiple sources.
New Blood-Brain Barrier search feature launched following user feedback
Beacon Intelligence has also introduced a new Blood-Brain Barrier search column across the Neurology and Psychiatric modules, following direct feedback from users.
Since the launch of Beacon Neuroscience, one of the most common requests from subscribers was for a quicker way to identify which assets had Blood-Brain Barrier preclinical data available. Previously, this information sat within the preclinical tab of each individual drug record, making it harder to scan and compare assets efficiently during early-stage reviews.
To solve this, Beacon has launched a simple Y/N BBB column within the drug search results, allowing users to instantly see which drugs have Blood-Brain Barrier data available without needing to open individual records.
The new feature is expected to save users significant research time while making it easier to compare neuroscience assets, prioritise opportunities and carry out competitive assessments with greater speed.
Built with users, designed for better decisions
All data within Beacon Neuroscience is manually curated and verified by Beacon’s in-house neuroscience team, with records updated daily to ensure users can work with trusted and current intelligence.
The platform combines structured ontologies, advanced filtering tools and specialist scientific expertise to help users uncover patterns and insights that can often remain hidden within fragmented or inconsistent public datasets.
Eloise Jarvis, Senior Researcher at Beacon, comments: “Neuroscience drug development remains one of the most complex areas of research, so having access to clear, reliable data is critical. These latest enhancements are about giving our users even greater visibility, whether that means understanding commercial activity in neurology, tracking psychiatric pipelines or quickly identifying Blood-Brain Barrier data during asset reviews.
“We continue to develop Beacon Neuroscience around the needs of the people using it every day, helping them move faster, ask better questions and make more confident decisions.”
Continuing to evolve
Beacon Neuroscience forms part of Beacon Intelligence’s wider portfolio of specialist life sciences datasets, which also span other disease areas including Oncology and CVRM, as well as modality specific datasets including, ADC, Bispecific, Cell Therapy and RNA.
The latest expansion reflects Beacon’s continued investment in building high-quality, user-led intelligence platforms that support smarter R&D, business development and competitive strategy decisions.
For organisations operating in neuroscience, the result is a stronger, broader and more practical intelligence platform built for the realities of modern drug development.
Find out more about how Beacon Neuroscience can accelerate your Neuroscience drug development decisions.
